Balaxi Pharmaceuticals Share Price

NSE
BALAXI •
BUY

1W Return

1M Return

6M Return

1Y Return

3Y Return

The current prices are delayed, login or Open Demat Account for live prices.
Start SIP in Balaxi Pharmaceuticals
Balaxi Pharmaceuticals Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Balaxi Pharmaceuticals Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
57.79% Fall from 52W High
-10.9
Dividend yield 1yr %
0

Balaxi Pharmaceuticals Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Balaxi Pharmaceuticals Quarterly Revenue

Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
73.29 Cr
77.38 Cr
65.62 Cr
59.83 Cr
60.78 Cr

Balaxi Pharmaceuticals Yearly Revenue

Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
238.65 Cr
339.07 Cr
284.36 Cr
233.56 Cr
48.44 Cr

Balaxi Pharmaceuticals Quarterly Net Profit/Loss

Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
5.36 Cr
4.59 Cr
6.48 Cr
10.93 Cr
13.59 Cr

Balaxi Pharmaceuticals Yearly Net Profit/Loss

Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
-2.39 Cr
45.96 Cr
47.66 Cr
38.14 Cr
6.1 Cr
Balaxi Pharmaceuticals Result Highlights
  • Balaxi Pharmaceuticals Ltd reported a 5.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 27.3%.

  • Its expenses for the quarter were up by 5.1% QoQ and 48.2% YoY.

  • The net profit increased 16.8% QoQ and decreased 60.6% YoY.

  • The earnings per share (EPS) of Balaxi Pharmaceuticals Ltd stood at 1 during Q3FY25.

    Read more

Data Source: BSE, Company announcements

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

Balaxi Pharmaceuticals shareholding Pattern

Promoter
66%
Foreign Institutions
16.5%
Public
17.5%
Promoter
66%
Foreign Institutions
16.5%
Public
17.5%
Promoter
66%
Foreign Institutions
16.9%
Public
17.1%
Promoter
66.9%
Foreign Institutions
17.2%
Public
15.9%
Promoter
71.2%
Foreign Institutions
18.6%
Public
10.2%
Promoter
71.2%
Foreign Institutions
18.6%
Public
10.2%

Balaxi Pharmaceuticals Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
1
Bearish Moving Averages
15
5Day EMA
65.70
10Day EMA
66.60
12Day EMA
66.50
20Day EMA
65.90
26Day EMA
65.70
50Day EMA
67.10
100Day EMA
73.40
200Day EMA
83.40
5Day SMA
66.40
10Day SMA
67.60
20Day SMA
65.60
30Day SMA
62.40
50Day SMA
65.30
100Day SMA
72.00
150Day SMA
82.00
200Day SMA
90.30
Delivery & Volume

Delivery & Volume

PeriodCombined Delivery VolumeNSE+BSE Traded Volume
Day Rs
143570 Rs
157932 Rs
Week Rs
105780 Rs
128027 Rs
Month Rs
492240 Rs
550918 Rs
Resistance & Support
64.04
Pivot
Resistance
First Resistance
65.78
Second Resistance
67.63
Third Resistance
69.37
Support
First Support
62.19
Second support
60.45
Third Support
58.60
Relative Strength Index
46.79
Money Flow Index
40.99
MACD
0.76
MACD Signal
1.07
Average True Range
4.69
Average Directional Index
23.26
Rate of Change (21)
14.06
Rate of Change (125)
-40.91

Balaxi Pharmaceuticals Company background

Founded in: 1942
Managing director: Ashish Maheshwari
Balaxi Ventures Limited was formerly incorporated in the name of The Anandam Rubber Company Limited on September 28, 1942. The Company changed its name from The Anandam Rubber Company Limited to Balaxi Ventures Limited on August 08, 2017. The Company incorporated with a basic objective of running rubber and tea plantations and owns several plantations across South India. In year 1989 the company sold its entire plantations to meet the emerging business needs and started concentrating in Investments and trading. The company previously was a investment company, but the company during the financial year 201819 has commenced the business of International Wholesale Trading of Pharmaceuticals, Builders Hardware and FMCG Products On 15 March 2017, Balaxi Overseas Private Limited (BOPL) entered into a Share Purchase Agreement (SPA) with the erstwhile promoters of Company (i.e. Mr. Nirej V. Paul, Mr. V. M. Paulose, Dr. Leelamma T. J and Mrs. Jaya Paul) to acquire 1,670,036 Equity Shares representing 54.94% of the paid up share capital of the Company along with the control over the Company, pursuant to which BOPL made an Open Offer under Regulation 3(1) and Regulation 4 of SEBI (SAST) Regulations, 2011. Control and management of the Company was acquired by BOPL on May 04, 2017 and it became the new promoter of Company and their representatives i.e. Mr. Ashish Maheshwari and Mrs. Minoshi Maheshwari became the new Directors of the Company. Simultaneously, erstwhile promoters stepped down as promoters from Company on same day and Mr. Nirej V. Paul and Dr. Leelamma TJ resigned as Managing Director and as Chairperson from the Company, respectively. Under the above said Open Offer, BOPL acquired 3,30,000 equity shares representing 10.86% equity share capital of the Company. On completion of the Open Offer BOPL became the holding and Promoter Company with an aggregate shareholding of 2000036 Equity Shares (ie 65.79%).The main objects of the company were amended to include activities of International wholesale trading in pharmaceutical, food products and builders hardware on August 08, 2018. The Company commenced the business of International Wholesale Trading of Pharmaceuticals, Builders Hardware and FMCG products from Financial Year 201819.Further, in February 2019, it kickstarted Food Products business by launching a range of biscuits under the brand YAP.The Company expanded its presence by establishing a central distribution warehouse in Guatemala, marking its entry into the third geography. This expansion helped in strengthening the distribution network and a wider customer base in 2019. In FY 2023, Company started operations in two Latin American Countries, i.e., Honduras and El Salvador and also started operations inthe Central African Republic.
Read More

Balaxi Pharmaceuticals FAQs

Balaxi Pharmaceuticals share price in the past 1-year return was -35.55. The Balaxi Pharmaceuticals share hit a 1-year low of Rs. 50.42 and a 1-year high of Rs. 151.45.

The market cap of Balaxi Pharmaceuticals is Rs. 352.89 Cr. as of 27/3/2025.

The PE ratios of Balaxi Pharmaceuticals is 84.11 as of 27/3/2025.

The PB ratios of Balaxi Pharmaceuticals is 2.77 as of 27/3/2025

You can easily buy Balaxi Pharmaceuticals shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Please be aware that Balaxi Pharmaceuticals stock prices are subject to continuous fluctuations due to various factors.

Open Demat Account
+91 -

personImage
Open Demat Account
+91 -